You are here: Los Angeles Business and Finance

Business News

BiPar Announces Upcoming Data Presentations Demonstrating Progress on PARP Inhibitor Drug Pipeline for Cancer

Distributed by Press Release

Brisbane, Calif. (Map) - BRISBANE, Calif., Oct. 22 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced that key data supporting its PARP (poly-ADP-ribose polymerase) inhibitor drug development programs will be presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco from Oct. 22 to 26 and the EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in Cancer" in Brussels, Nov. 15 to 17.

PARP is a novel, validated target for cancer treatment. PARP1 plays a central role in cell proliferation and in DNA repair. BiPar scientists will present results showing that PARP1 gene expression is significantly upregulated in many but not all tumor types. BiPar's novel, proprietary PARP inhibitors are members of a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinical studies suggest the drugs selectively inhibit tumor cell proliferation and are active against a broad range of tumor types. BiPar is initiating Phase 1b and Phase 2 clinical trials of BSI-201, its lead PARP inhibitor, in several major cancers. That research program has been directed in large part by the molecular biomarker data being presented at these meetings.

"These findings will focus our efforts on those tumor types with the greatest opportunity for clinical success," said Barry Sherman, M.D., BiPar's executive vice president. "With this information we believe we will be able to efficiently exploit our pipeline of PARP inhibitors that target major unmet needs in cancer."

    The schedule of presentations is as follows:
    Title:      The novel PARP-1 inhibitor, BSI-401, has antitumor activity
                and potentiates oxaliplatin cytotopic activity in human
                pancreatic cancer
    When:       Wednesday, Oct. 24, 2007, 12:30 p.m. PDT
    Where:      AACR-NCI-EORTC International Conference on Molecular Targets
                and Cancer Therapeutics, Moscone West Convention Center, San
                Francisco
    Presenter:  Davide Melisi, M.D., Department of Gastrointestinal Medical
                Oncology, University of Texas M.D. Anderson Cancer Center
    Title:      PARP-1 gene over-expression in primary human cancers: A
                potential marker for PARP inhibition.
    When:       Thursday, Oct. 25, 2007, 12:30 p.m. PDT
    Where:      AACR-NCI-EORTC International Conference on Molecular Targets
                and Cancer Therapeutics, Moscone West Convention Center, San
                Francisco
    Presenter:  Valeria Ossovskaya, Ph.D.  Director of Preclinical
                Development, BiPar
    Title:      The PARP1 gene is over-expressed in triple negative breast
                cancer
    When:       Thursday, Nov. 15, 6 to 8 p.m. CEST
    Where:      EORTC-NCI-ASCO Annual Meeting on "Molecular Markers in
                Cancer," Sheraton Brussels, Hotel & Towers, Brussels, Belgium
    Presenter:  Valeria Ossovskaya, Ph.D. Director of Preclinical Development,
                BiPar

About BiPar Sciences

BiPar Sciences Inc. (http://www.biparsciences.com) is a clinical-stage biopharmaceutical company developing and commercializing a pipeline of novel, tumor-selective drugs designed to meet the significant unmet needs of cancer patients.

pr